Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the efficiency and safety of combined extracorporeal blood purification in patients with septic shock in Neurosurgical ICU in comparison with the efficiency and safety of the continuous renal replacement therapy (CRRT).
According to studies and modern sepsis treatment guidelines, conventional CRRT has not proved effective in the septic shock treatment.
Effectiveness of other extracoporeal blood purification methods, such as hemoadsorption or combined blood purification (hemoadsorption combined with CRRT) is widely pointed out in current publications: contemporary studies in general ICU patients demonstrated that the use of hemoadsorption or combined extracorporeal blood purification methods is effective for septic shock patients treatment.
It has been proven that cytokines discharged into the systemic blood flow are the key pathophysiological mechanism of septic shock. Hemoadsorption allows for significantly more effective removal of different inflammatory mediators than the traditional methods of CRRT. The combined extracorporeal blood purification method demonstrated similar efficacy in general ICU patients.
The aim of this study is to assess the efficiency and safety of combined extracorporeal blood purification in with septic shock in neurosurgical ICU in comparison with the efficiency and safety of the continuous renal replacement therapy (CRRT) with AN69 membrane.
Study novelty: We have not encountered published studies evaluating the efficiency of combined extracorporeal blood purification methods in neurosurgical patients with septic shock. Furthermore, currently there is not enough data to compare combined extracorporeal blood purification with CRRT for septic shock treatment. The planned study is the first to investigate the safety and efficiency of combined extracorporeal blood purification in patients with septic shock in neurosurgical ICU.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Combined extracorporeal blood purification | Experimental | CRRT with CVVHDF mode plus treatment with CytSorb adsorber |
|
| Control | Active Comparator | CRRT with CVVHDF mode |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Combined extracorporeal blood purification | Procedure | Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber. |
| Measure | Description | Time Frame |
|---|---|---|
| Vasopressor dose reduction | Vasopressor dose reduction value | 6, 12, 24, 48 and 72 hours after the randomization time |
| Time on vasopressor support | Time on vasopressor support | Up to 28 days after the randomization date |
| SOFA score reduction | SOFA score reduction | 24, 48 and 72 hours after the randomization time |
| Measure | Description | Time Frame |
|---|---|---|
| Interleukins concentration reduction | Interleukins (IL-1β, IL-6, IL-8, IL-10) concentration reduction | 6, 12, 24 and 48 hours after the randomization time |
| Tumor necrosis factor-α concentration reduction |
| Measure | Description | Time Frame |
|---|---|---|
| Intracranial hemorrhagic complication | Presence of any intracranial hemorrhagic complications | in 48 hours after the randomization time |
| Extracranial hemorrhagic complication | Presence of extracranial hemorrhagic complications |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Aleksandr Burov | Contact | +79854215478 | Aleksander.bour@mail.ru | |
| Gleb Danilov, Phd | Contact | gdanilov@nsi.ru |
| Name | Affiliation | Role |
|---|---|---|
| Aleksandr Burov | N. N. Burdenko National Medical Research Center of Neurosurgery | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Federal State Autonomous Institution "N .N. Burdenko National Medical Research Center of Neurosurgery" of the Ministry of Healthcare of the Russian Federation | Recruiting | Moscow | 125047 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| CRRT | Procedure | Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter) |
|
Tumor necrosis factor-α concentration reduction
| 6, 12, 24 and 48 hours after the randomization time |
| Total bilirubin concentration reduction | Total bilirubin concentration reduction | 6, 12, 24 and 48 hours after the randomization time |
| C - reactive protein level reduction | C - reactive protein level reduction | 24, 48 and 72 hours after the randomization time |
| Procalcitonin concentration reduction | Procalcitonin concentration reduction | 6, 12, 24, 48 and 72 hours after the randomization time |
| PiCCO-derived parameters normalization | Any PiCCO-derived parameter normalization | 6, 12, 24, 48 and 72 hours after the randomization time |
| Arteriovenous pCO2 gap reduction | Arteriovenous pCO2 gap reduction | 6, 12, 24, 48 and 72 hours after the randomization time |
| Arterial blood lactate level reduction | Arterial blood lactate level reduction | 6, 12, 24, 48 and 72 hours after the randomization time |
| ICU length of stay | ICU length of stay | up to 3 months after the randomization date |
| Hospital stay time | Hospital stay time | up to 3 months after the randomization date |
| Mechanical ventilation time | Mechanical ventilation time | up to 3 months after the randomization date |
| Continuous renal replacement therapy time | Continuous renal replacement therapy time | up to 3 months after the randomization date |
| in 48 hours after the randomization time |
| Death in 28-days after CRRT inititiation | 28-days mortality in the observed sample group | 28-days after the randomization date |
| In-hospital death | Hospital mortality in the observed sample group | in 3 months after the randomization date |
| Albumin blood level reduction | Albumin blood level reduction of more than 10% | 24 and 48 hours after the randomization time |
|
| D010335 |
| Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |